Raloxifene: a selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women

Author： Vogel Victor G  

Publisher： Future Medicine

ISSN： 1745-5057

Source： Women's Health, Vol.3, Iss.2, 2007-03, pp. : 139-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis – a clinical update on efficacy and safety

By Deal Chad L   Draper Michael W  

Women's Health, Vol. 2, Iss. 2, 2006-03 ,pp. : 199-210

Future Medicine

Access to resources Recommend Favorite

Estrogen Therapy and Breast Cancer in Postmenopausal Women†

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 28, Iss. 6, 1980-06 ,pp. : 251-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bazedoxifene: a selective estrogen-receptor modulator

By Mitwally Mohamed FM  

Women's Health, Vol. 4, Iss. 4, 2008-07 ,pp. : 319-326

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

By Palacios Santiago  

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1553-1563

Informa Healthcare

Access to resources Recommend Favorite

Active smoking and the risk of estrogen receptor‐positive and triple‐negative breast cancer among women ages 20 to 44 years

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 1026-1034

John Wiley & Sons Inc

Access to resources Recommend Favorite